INTERNATIONAL JOURNAL OF
PHARMACEUTICAL AND HEALTHCARE INNOVATION
journal homepage: www.ijphi.com

OPEN ACCESS

Review Article

Pharmacogenomics in Psychiatry: Optimizing Psychotropic Drug Therapy - A Comprehensive Review

Thanshifa Fathima[1], Ramdas Bhat[2]*

[1]PG scholar, Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Farangipete Post, Mangalore, Karnataka, India. 574143

[2]Associate Professor, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Farangipete Post, Mangalore, Karnataka, India. 5741432

Article Info

Article history:

Manuscript ID:

IJPHI2430062024
Received: 24- July -2024
Revised :30- September -2024
Accepted: 06- October 2024
Available online: October 2024

Keywords:
Pharmacogenomics, Psychiatry, Personalized Medicine, Gene-Drug Interactions, Treatment Optimization

.****Corresponding Author:***
ramdas21@gmail.com

Abstract

*Pharmacogenomics is emerging as a promising approach to optimize psychotropic drug therapy in psychiatry. This comprehensive review explores the potential of pharmacogenomics to address the challenges of individual variability in patient responses to psychiatric medications. The fundamentals of pharmacogenomics are discussed, including relevant genetic variations such as Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), and haplotypes that influence drug metabolism and efficacy. The review examines key gene-drug interactions in psychiatry, such as the relationship between the CYP2D6 gene and antidepressants, and the HLA-B*15:02 allele with carbamazepine. Clinical applications are explored, highlighting guidelines from organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and real-world case studies demonstrating improved treatment outcomes through pharmacogenomic testing. Challenges and limitations in implementing pharmacogenomics in psychiatric practice are addressed, including technical issues in standardization of genetic testing, clinical integration hurdles, and ethical concerns surrounding genetic privacy and potential discrimination. The review also looks ahead to future frontiers in psychiatric pharmacogenomics, discussing emerging technologies like next-generation sequencing and machine learning applications. Despite current challenges, pharmacogenomics holds significant promise for personalizing and optimizing psychiatric treatment. As research progresses and new technologies are integrated into clinical practice, the field is poised to revolutionize mental health care, moving towards more precise, effective, and patient-centered treatment strategies. This shift represents a significant advancement in addressing the global burden of psychiatric disorders and improving patient outcomes.*

Introduction

Psychiatric disorders pose a significant global health challenge, impacting numerous individuals and placing a substantial burden on healthcare systems worldwide [1]. These disorders, which range from depression and anxiety to schizophrenia and bipolar disorder, can greatly affect a person's quality of life, relationships, and societal functioning [2]. Psychotropic medications such as antidepressants, antipsychotics, mood stabilizers, and anxiolytics have traditionally been a key component of treating these conditions. These medications function by adjusting neurotransmitter systems in the brain to alleviate symptoms and enhance overall mental well-being. However, their efficacy is not consistent, and individual responses can vary widely [3]. The complexity of psychotropic drug therapy lies in the personalized nature of patient reactions. What may be effective for one individual could prove ineffective or harmful for another due to a combination of factors such as genetic variations, environmental influences, and individual physiological characteristics. Therefore, the current method of prescribing psychotropic medications often involves a trial-and-error approach [4]. Psychiatrists typically begin with a standard medication and dosage, adjusting the treatment plan based on the patient's response over time. This process can be frustrating and time-consuming for both patients and healthcare providers, potentially delaying effective treatment and exposing patients to unnecessary side effects. Additionally, this approach can lead to increased healthcare expenses, decreased medication adherence, and sometimes a worsening of symptoms before an effective treatment is identified [5].

Pharmacogenomics offers a promising solution to these challenges by examining how an individual's genetic composition impacts their response to medications. By evaluating specific genetic markers linked to drug metabolism, neurotransmitter activity, and other pertinent biological processes, pharmacogenomic testing can offer valuable insights into how a patient may react to various medications. This information can help psychiatrists choose the most suitable drug and dosage for each patient, potentially reducing the time needed to find an effective treatment and minimizing adverse effects [6]. The integration of pharmacogenomics into psychiatric care offers the potential for a more precise, effective, and patient-centered treatment approach, with the capacity to significantly enhance outcomes for individuals with psychiatric disorders on a global scale [7,8].

Fundamentals of Pharmacogenomics and Relevant Genetic Variations

Pharmacogenomics is a progressive area of study that integrates pharmacological principles with genomics discoveries to transform drug development and prescription practices. The primary focus of pharmacogenomics is to comprehend how an individual's genetic composition impacts their reaction to medications, aiming to create and recommend drugs that are both more efficient and safer for each patient. This tailored medical approach considers the subtle genetic variations among individuals that can significantly influence drug metabolism, effectiveness, and potential adverse effects. Through the analysis of an individual's genetic characteristics, healthcare providers can make more educated decisions regarding medication selection and dosage, potentially preventing negative reactions and enhancing treatment outcomes. The realm of pharmacogenomics goes beyond drug selection, also playing a critical role in drug development by aiding pharmaceutical companies in formulating medications that target specific genetic variations linked to diseases or drug responses [9,10].

At the core of pharmacogenomics lies the investigation of pertinent genetic variances that can impact drug reactions. Single Nucleotide Polymorphisms (SNPs) are among the most prevalent types of genetic variations scrutinized. These involve single base pair modifications in DNA sequences that can influence protein function or expression levels, potentially changing how an individual metabolizes or responds to a drug. Another significant category of genetic variation is Copy Number Variations (CNVs), which encompass larger DNA segments that have been deleted, duplicated, or rearranged, leading to a substantial

impact on gene dosage and function. Haplotypes, which are assortments of genetic variations inherited together, also hold importance in pharmacogenomic investigations. Specific haplotypes can be linked to distinct drug response tendencies, offering valuable insights for treatment determinations. Through the examination of these diverse genetic variations, researchers and healthcare professionals can acquire a more comprehensive understanding of how genetic factors influence drug responses, opening avenues for more individualized and efficient treatment approaches across various medical domains, including psychiatry [11-13].

Pharmacogenomics and its impact on psychiatric treatment

Pharmacogenomics has emerged as a transformative domain in psychiatry, providing insights into the correlation between an individual's genetic composition and their reaction to psychotropic drugs. This paradigm is crucial in psychiatric interventions, given the wide-ranging variations in patient responses to medications. Genetic discrepancies can significantly impact drug metabolism, passage across biological barriers, and binding to brain receptors, explaining why some patients benefit from standard doses while others experience adverse reactions or minimal response. Genetic variations in enzymes responsible for drug metabolism, particularly those in the cytochrome P450 family, can modify medication metabolism rates, potentially leading to drug accumulation or rapid elimination. By understanding these genetic influences, psychiatrists can make more judicious decisions regarding medication selection and dosages [14,15].

Several pivotal gene-drug interactions have been identified in psychiatric pharmacogenomics. The association between the CYP2D6 gene and antidepressants is extensively studied, with genetic variations categorizing individuals as poor, intermediate, extensive, or ultra-rapid metabolizers. The HLA-B*15:02 allele's interaction with carbamazepine can heighten the risk of severe cutaneous adverse reactions. Additionally, variations in the serotonin transporter gene (5-HTTLPR) have been linked to differing responses to selective serotonin reuptake inhibitors (SSRIs). These examples underscore the potential of pharmacogenomics in tailoring psychiatric treatment, moving from a uniform approach to a more personalized strategy. As advancements in this field continue, there is potential for revolutionizing psychiatric care, leading to more efficient, safer, and personalized treatment approaches for individuals with mental health conditions [16,17].



Fig. 1: Key Concepts and Applications of Pharmacogenomics in Psychiatry

Clinical applications of pharmacogenomics in psychiatry

The integration of pharmacogenomics into clinical psychiatric practice marks a significant step towards personalized medicine. Organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), and Canadian Pharmacogenomics Network for Drug Safety (CPNDS) have developed evidence-based guidelines for applying genetic information to drug prescribing. These guidelines cover various psychiatric medications, offering recommendations on interpreting genetic test results and adjusting treatment strategies. They typically categorize patients into different metabolizer groups based on genetic profiles and provide specific dosing recommendations or alternative medication suggestions for each group [18].

The real-world impact of pharmacogenomic testing in psychiatry is best illustrated through case studies. For instance, one case might describe a patient with major depressive disorder who failed to respond to multiple antidepressants but found relief after genetic testing revealed a CYP2D6 gene variant,

leading to an alternative medication prescription. Another case could involve a bipolar disorder patient experiencing rapid cycling due to being an ultra-rapid metabolizer of their prescribed mood stabilizer; adjusting the dosage based on genetic information helped stabilize their mood. These examples highlight the potential benefits of pharmacogenomic testing, illustrate the complexities of interpreting genetic information in clinical practice, and often reveal the cost-effectiveness of this approach by reducing time spent on ineffective treatments and minimizing adverse drug reactions [19,20].

Challenges and limitations in pharmacogenomics for psychiatry

Pharmacogenomics in psychiatry faces significant technical, clinical, and ethical challenges. Technically, the lack of standardization in genetic testing methods can lead to inconsistent results across laboratories, potentially compromising data reliability. Interpreting complex genetic data requires sophisticated bioinformatics tools and expertise, which may not be universally available. Clinically, integrating pharmacogenomics into existing healthcare systems requires significant changes to workflows and electronic health records. Many healthcare providers lack training in genomics, feeling ill-equipped to apply genetic information in clinical decision-making. There's also a risk of over-relying on genetic data at the expense of other important clinical factors [21,22].

Ethical considerations add another layer of complexity. Privacy concerns are paramount, given the sensitive nature of genetic information and the risk of data breaches. The potential for genetic discrimination, particularly in mental health where stigma already poses challenges, is a serious concern. While laws like the Genetic Information Nondiscrimination Act provide some protections, there are still worries about how genetic information might be used by employers or insurers. These challenges underscore the need for robust policies and safeguards to protect patient privacy and prevent misuse of genetic information as pharmacogenomics becomes more integrated into psychiatric care [23,24].

Future frontiers in psychiatric pharmacogenomics

The future of pharmacogenomics in psychiatry holds exciting possibilities for enhancing treatment precision and efficacy. Emerging technologies like next-generation sequencing are poised to provide more comprehensive genetic profiles at lower costs, potentially expanding the scope of genetic markers analyzed in clinical settings. Machine learning algorithms are increasingly being applied to interpret complex genomic data, offering the potential to uncover new patterns and relationships between genetic variations and drug responses. The field is also expanding beyond genetics to incorporate epigenetics and other -omics data, such as proteomics and metabolomics, which could provide a more holistic view of an individual's biological response to medications. However, realizing the full potential of these advancements requires large-scale, diverse studies to validate pharmacogenomic markers across different populations. Such studies are crucial for ensuring that the benefits of pharmacogenomics are applicable to all patient groups and for identifying population-specific genetic factors that may influence drug response. As these research efforts progress and new technologies are integrated into clinical practice, the field of psychiatric pharmacogenomics is likely to see significant advancements in its ability to personalize and optimize treatment strategies for mental health disorders.

Conclusion

Pharmacogenomics offers a revolutionary approach to psychiatric treatment, using genetic information to optimize psychotropic drug therapy. This field promises enhanced efficacy, reduced side effects, and improved outcomes. While challenges in standardization, implementation, and ethics persist, ongoing research and technological advances are addressing these issues. As studies validate genetic markers and new technologies improve data interpretation, personalized psychiatric care is becoming a reality. The integration of pharmacogenomics into clinical practice represents

a significant shift towards more precise, effective, and patient-centered mental health treatments.

Conflict of Interest: None.

Financial support: None.

Ethical statement: None.

Reference

1. Wainberg ML, Scorza P, Shultz JM, Helpman L, Mootz JJ, Johnson KA, et al. Challenges and Opportunities in Global Mental Health: A Research-to-Practice Perspective. Curr Psychiatry Rep. 2017;19(5):28.
2. Okpaku SO. The challenges and opportunities for global mental health. In: Innovations in Global Mental Health. Cham: Springer Int Publ; 2021. p. 1–26.
3. Ernstmeyer K, Christman E. Chapter 6 Psychotropic Medications [Internet]. NCBI Bookshelf. 2022 [cited 2024 Jul 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK590034/
4. Ali MM, Taha MM, Ahmed AE, Ali S, Baiti MA, Alhazmi AA, et al. Psychotropic Medication Adherence and Its Associated Factors Among Schizophrenia Patients: Exploring the Consistency of Adherence Scales. Cureus. 2023;15(9)
5. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387-409.
6. Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals. 2024;17(7):940.
7. Cuéllar-Barboza AB, McElroy SL, Veldic M, Singh B, Kung S, Romo-Nava F, et al. Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. Int J Bipolar Disord. 2020;8(1):1-7.
8. Alchakee A, Ahmed M, Eldohaji L, Alhaj H, Saber-Ayad M. Pharmacogenomics in psychiatry practice: the value and the challenges. Int J Mol Sci. 2022;23(21):13485.
9. Lopez D. Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. Int J Biomed Investig. 2018;1(2):1-16.
10. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 2024;16(3):332.
11. González-Covarrubias V, Lozano K, Texis T, Guzmán-Cruz CK, Rodríguez-Dorantes M, Rubio-Carrasco K, et al. Pharmacogenomics: Current Actionable Variants. Revista de investigaci﷿n Cl﷿nica. 2021;72(5):271-9.
12. Schmidt MA, Schmidt CM, Goodwin TJ. Pharmacogenomics in Spaceflight. Handbook of Space Pharmaceuticals. 2022;389–427.
13. Panda G, Mishra N, Sharma D, Kutum R, Bhoyar RC, Jain A, et al. Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum. Frontiers in Pharmacology. 2022;13(1):1-19.
14. Pardiñas AF, Owen MJ, Walters JT. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron. 2021;109(24):3914-29.
15. Andreassen OA, Hindley GF, Frei O, Smeland OB. New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. World Psychiatry. 2023;22(1):4-24.
16. Kee PS, Maggo SD, Kennedy MA, Chin PK. The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses. Frontiers in pharmacology. 2023;14:1080117.
17. Palumbo S, Mariotti V, Pellegrini S. A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical

Resources. Journal of Clinical Psychopharmacology. 2024;44(1):49-56.
18. van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Frontiers in Psychiatry. 2020;11:94.
19. Virelli CR, Mohiuddin AG, Kennedy JL. Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis. Translational psychiatry. 2021;11(1):509.
20. Berrou I, Ramsunder A, Palmer R. Making the case for pharmacogenomics in the management of mental health conditions. Pharm J. 2023;310(7969):1-34.
21. Herr TM, Peterson JF, Rasmussen LV, Caraballo PJ, Peissig PL, Starren JB. Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network. Journal of the American Medical Informatics Association. 2018;26(2):143–8.
22. Martinez-Martin N, Magnus D. Privacy and ethical challenges in next-generation sequencing. Expert Review of Precision Medicine and Drug Development. 2019;4(2):95–104.
23. Rodríguez-Yunta E. Ethical and social issues in research on genetics and mental health. Salud mental. 2023;46(5):251-9.